- Home
- BKE vs AKRO Comparison
BKE vs AKRO Comparison
Compare BKE & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKE
- AKRO
- Stock Information
- Founded
- BKE 1948
- AKRO 2017
- Country
- BKE United States
- AKRO United States
- Employees
- BKE N/A
- AKRO N/A
- Industry
- BKE Clothing/Shoe/Accessory Stores
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BKE Consumer Discretionary
- AKRO Health Care
- Exchange
- BKE Nasdaq
- AKRO Nasdaq
- Market Cap
- BKE 2.4B
- AKRO 2.0B
- IPO Year
- BKE 1992
- AKRO 2019
- Fundamental
- Price
- BKE $48.79
- AKRO $25.60
- Analyst Decision
- BKE Hold
- AKRO Strong Buy
- Analyst Count
- BKE 1
- AKRO 8
- Target Price
- BKE $46.00
- AKRO $46.83
- AVG Volume (30 Days)
- BKE 542.6K
- AKRO 842.7K
- Earning Date
- BKE 03-14-2025
- AKRO 02-27-2025
- Dividend Yield
- BKE 8.05%
- AKRO N/A
- EPS Growth
- BKE N/A
- AKRO N/A
- EPS
- BKE 3.94
- AKRO N/A
- Revenue
- BKE $1,220,873,000.00
- AKRO N/A
- Revenue This Year
- BKE N/A
- AKRO N/A
- Revenue Next Year
- BKE $2.62
- AKRO N/A
- P/E Ratio
- BKE $12.39
- AKRO N/A
- Revenue Growth
- BKE N/A
- AKRO N/A
- 52 Week Low
- BKE $34.87
- AKRO $15.32
- 52 Week High
- BKE $54.25
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- BKE 43.00
- AKRO 44.22
- Support Level
- BKE $47.03
- AKRO $21.34
- Resistance Level
- BKE $52.68
- AKRO $28.94
- Average True Range (ATR)
- BKE 1.46
- AKRO 1.35
- MACD
- BKE -0.42
- AKRO -0.09
- Stochastic Oscillator
- BKE 30.59
- AKRO 56.05
About BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to better-priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.